Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24732108 | 0.83 | NR1H2 (0.42) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL22165552 | 0.82 | HTT (0.43) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL17926078 | 0.82 | NR1H2 (0.41) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL31368516 | 0.82 | NR1H2 (0.45) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL22615432 | 0.81 | ADORA1 (0.42) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL22143168 | 0.80 | MAPT (0.40) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL24732124 | 0.80 | NR1H2 (0.41) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL12255700 | 0.80 | NR1H2 (0.40) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL24730619 | 0.79 | HTT (0.41) | POLBNR1H2HTTATMESR2 | |
| SCHEMBL24732088 | 0.79 | GPR119 (0.43) | POLBNR1H2HTTATMESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343742-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2024-10-17 | — | — | US | disclosed |
| US-11999752-B2 | Vinyl imidazole compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2022047093-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220064188-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2022-03-03 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | POLB 1146/4885NR1H2 2586/4885HTT 3652/4885 |
| US-20240343742-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | POLB 813/4885NR1H2 2650/4885HTT 3348/4885 |
| US-20220064188-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | POLB 813/4885NR1H2 2650/4885HTT 3348/4885 |
| US-11999752-B2 | Vinyl imidazole compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | POLB 813/4885NR1H2 2650/4885HTT 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.